ArticleNature communications2025
Designing an oxidase toolbox for site-directed oxidation of taxanes.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Paclitaxel is one of the most prominent drugs for cancer therapy, and its synthesis has long been pursued by scientific community. Although the biosynthetic pathway has been gradually unraveled, its synthetic efficiency remains severely constrained by the low activity and low product selectivity of the hydrolases involved. In this study, an artificial toolbox of oxidases derived from mutants of TteUPO (unspecific peroxygenase from Thielavia terrestris) is developed for site-directed oxidation of taxanes at the C-4, C-6, C-10, C-11, C-12, and C-13 positions. Furthermore, de novo biosynthesis of oxidized taxadiene products is achieved in an engineered E. coli chassis. These findings offer an unconventional strategy for developing an efficient route toward paclitaxel and constructing paclitaxel analogs with different structures for medicinal evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.